A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Enveric Biosciences, Inc.
ENVB
$4M
Mkt Cap
$1.29
-2.27%
Enveric Biosciences, Inc. (ENVB) has a 5-year average return on invested capital (ROIC) of -73.7%. This is below average and may indicate limited pricing power.
Enveric Biosciences, Inc. (ENVB) has a market capitalization of $4M. It is classified as a small-cap stock.
Enveric Biosciences, Inc. (ENVB) does not currently pay a regular dividend.
Enveric Biosciences, Inc. (ENVB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Enveric Biosciences, Inc. (ENVB) reported annual revenue of $-0 thousand in its most recent fiscal year, based on SEC EDGAR filings.
Enveric Biosciences, Inc. (ENVB) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Enveric Biosciences, Inc. (ENVB) has a debt-to-equity ratio of 0.22. This indicates a conservatively financed balance sheet.
Item 1. Business We were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior to the completion of a “reverse merger” transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc., a Delaware corporation (the “2015 Merger”). In connection with the 2015 Merger, we changed our name to “AMERI Holdings, Inc.” The Ameri business ceased to be part of the Company on December 30, 2020, pursuant to a spin-off transaction. On December 30, 2020, we completed a tender offer to purchase all of the outstanding common shares of Jay Pharma Inc., a Canada corporation, for shares of Company common stock or certain preferred stock, and changed our name to “Enveric Biosciences, Inc.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 4K | - | 40M |
| Net Income | 0 | - | - | - | -19M | -6.0M |
| EPS | $-12.08 | $-12.08 | $-1,523.20 | $-269.53 | $-28.89 | $-263.80 |
| Free Cash Flow | -8.1M | -8.1M | -7.7M | -14M | -18M | -732K |
| ROIC | -136.0% | - | - | - | -101.7% | -45.8% |
| Gross Margin | - | - | - | - | - | 20.4% |
| Debt/Equity | 0.00 | 0.22 | 0.94 | 1.20 | 0.00 | -3.43 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -8.8M | -8.8M | -9.6M | -16M | -27M | -2.3M |
| Operating Margin | 0.0% | - | -4398295.0% | -443593.3% | - | -5.8% |
| ROE | 0.0% | - | - | - | -101.7% | - |
| Shares Outstanding | 3M | 3M | 0M | 0M | 1M | 0M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 20M | 36M | 49M | 43M | 40M | N/A | 4K | 0 | 0 | 0 |
| Gross Margin | 33.9% | 19.2% | 21.1% | 20.9% | 20.4% | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | 55K | N/A | N/A | N/A | 8.0M | 7.3M | 2.8M | 2.8M | 2.8M |
| SG&A | 5.7M | 9.4M | 19M | 11M | 2.3M | 12M | 8.9M | 6.5M | 5.8M | 5.8M |
| EBIT | -794K | -5.4M | -11M | -7.1M | -2.3M | -27M | -16M | -9.6M | -8.8M | -8.8M |
| Op. Margin | -3.9% | -14.9% | -22.4% | -16.6% | -5.8% | N/A | -443593.3% | -4398295.0% | N/A | 0.0% |
| Net Income | -814K | -2.8M | -11M | N/A | -6.0M | -19M | N/A | N/A | N/A | 0 |
| Net Margin | -4.0% | -7.7% | -23.0% | N/A | -15.1% | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 400K | 8.2M | 8.2M | 1.5M | 1.0M | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | -10.7% | -27.0% | -66.1% | N/A | -45.8% | -101.7% | N/A | N/A | N/A | -136.0% |
| ROE | -314.9% | -46.6% | -71.8% | N/A | N/A | -101.7% | N/A | N/A | N/A | 0.0% |
| ROA | -11.8% | -10.4% | -24.3% | N/A | N/A | -81.3% | N/A | N/A | N/A | 0.0% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -3.9M | -2.7M | -2.7M | -2.6M | -648K | -17M | -14M | -7.7M | -8.1M | -8.1M |
| Free Cash Flow | -3.9M | -2.7M | -2.7M | -2.6M | -732K | -18M | -14M | -7.7M | -8.1M | -8.1M |
| Owner Earnings | -6.8M | -5.5M | -13M | -6.1M | -3.5M | -20M | -17M | -9.8M | -9.2M | -9.2M |
| CapEx | 0 | 29K | 5K | 6K | 84K | 584K | 5K | 0 | 0 | 0 |
| Maint. CapEx | 166K | 1.4M | 3.2M | 2.9M | 2.3M | 179K | 358K | 489K | 201K | 201K |
| Growth CapEx | N/A | 0 | 0 | 0 | 0 | 405K | 0 | N/A | N/A | 0 |
| D&A | 166K | 1.4M | 3.2M | 2.9M | 2.3M | 179K | 358K | 489K | 201K | 201K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 2.8M | 1.5M | 7.1M | 600K | 624K | 2.6M | 2.2M | 1.6M | 827K | 827K |
| Debt Repayment | 0 | 0 | 2.2M | 2.0M | 1.3M | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | 5.6M | 4.1M | 1.8M | 3.8M | 5.8M | -18M | N/A | N/A | N/A | -4.7M |
| Cash & Equiv. | 1.9M | 1.4M | 4.9M | 1.4M | 431K | 18M | 2.3M | 2.2M | 4.7M | 4.7M |
| Long-Term Debt | 5.0M | 1.5M | 1.1M | 0 | 740K | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 28.90 | 0.47 | 0.34 | -79.65 | -3.43 | 0.00 | 1.20 | 0.94 | 0.22 | 0.00 |
| Interest Coverage | -3.3 | -7.2 | -18.9 | -9.8 | -28.1 | -5222.9 | -4435.9 | -43982.9 | -82777.8 | -82777.8 |
| Equity | 259K | 12M | 19M | -65K | -1.8M | 15M | 2.0M | 1.6M | 4.2M | 4.2M |
| Total Assets | 14M | 40M | 52M | 30M | N/A | 20M | 4.3M | 3.1M | 5.1M | 5.1M |
| Total Liabilities | 14M | 28M | 33M | 19M | N/A | 4.0M | 2.3M | 1.5M | 918K | 918K |
| Intangibles | 3.1M | 8.8M | 9.5M | 5.8M | N/A | 380K | 211K | 42K | N/A | N/A |
| Retained Earnings | -1.1M | -3.8M | -15M | -34M | -4.9M | -79M | -96M | -106M | -115M | -115M |
| Working Capital | -1.4M | -2.6M | -16M | -4.6M | -14M | 14M | 1.2M | 1.2M | 4.0M | 4.0M |
| Current Assets | 7.2M | 10M | 15M | 10M | 109K | 18M | 3.6M | 2.7M | 4.9M | 4.9M |
| Current Liabilities | 8.6M | 13M | 30M | 15M | 15M | 4.0M | 2.3M | 1.5M | 918K | 918K |
| Per Share Data | ||||||||||
| EPS | -8.13 | -24.38 | -87.08 | -4,753.59 | -263.80 | -28.89 | -269.53 | -1,523.20 | -12.08 | -12.08 |
| Owner EPS | -68.36 | -48.43 | -101.69 | -832.40 | -154.65 | -30.65 | -202.02 | -1,153.72 | -2.88 | -2.88 |
| Book Value | 2.58 | 102.28 | 151.70 | -8.98 | -79.21 | 22.55 | 23.81 | 187.94 | 1.31 | 1.31 |
| Cash Flow/Share | -38.96 | -23.71 | -21.38 | -351.86 | -28.33 | -26.35 | -171.50 | -911.62 | -2.56 | 0.06 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 0.1M | 0.1M | 0.1M | 0.0M | 0.0M | 0.7M | 0.1M | 0.0M | 3.2M | 3.2M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 7.4 | 2.4 | 2.3 | 0.5 | N/A | N/A | N/A | N/A | 1.0 |
| Price/Sales | N/A | 2.3 | 1.9 | 4.8 | 0.3 | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -3.2% | -6.0% | -10.4% | -14.3% | N/A | N/A | N/A | N/A | -198.2% |
| Market Cap | 0 | 86M | 46M | 25M | 5.1M | 0 | 0 | 0 | 0 | 4.1M |
| Avg. Price | 0.00 | 85,568,656.13 | 85,478,211.46 | 19,415,303.57 | 3,490,947.86 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29 |
| Year-End Price | 0.00 | 87,885,000.00 | 41,850,000.00 | 2,335,500.00 | 1,296,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29 |
Enveric Biosciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 20.4%.
Enveric Biosciences, Inc. (ENVB) reported earnings per share (EPS) of $-12.08 in its most recent fiscal year.
Enveric Biosciences, Inc. (ENVB) has a 5-year average gross margin of 20.4%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 9 years of financial data for Enveric Biosciences, Inc. (ENVB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Enveric Biosciences, Inc. (ENVB) has a book value per share of $1.31, based on its most recent annual SEC filing.